Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus NABUMETONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus NABUMETONE.
BUTAZOLIDIN vs NABUMETONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA), is responsible for its therapeutic effects.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
1000 mg orally once daily with food; may increase to 1500-2000 mg/day in divided doses if needed.
None Documented
None Documented
Clinical Note
moderateNabumetone + Gatifloxacin
"Nabumetone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNabumetone + Rosoxacin
"Nabumetone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNabumetone + Levofloxacin
"Nabumetone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNabumetone + Trovafloxacin
"Nabumetone may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life is approximately 22-30 hours in healthy adults, allowing once-daily dosing. Steady state is achieved after 3-5 days.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Approximately 80% of a dose is excreted in urine as metabolites (primarily 6-methoxy-2-naphthylacetic acid and its glucuronide conjugates), with about 10% excreted in feces. Biliary excretion is minimal.
Category C
Category D/X
NSAID
NSAID